ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Ovarian Cancer
Cancer
Colorectal Cancer
Endometrial Cancer

Triple Negative Breast Cancer trials near Paris, Île-de-France, FRA:

Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (SKYLINE)

This is a phase II study, preceded by a safety run-in, with two independent cohorts (cohort A in early Triple Negative Breast...

Active, not recruiting
Triple Negative Breast Cancer
Biological: Tumor samples analysis
Biological: Blood samples analysis: Circulating Tumor DNA

Phase 2

Institut Curie

Paris, France and 1 other location

Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)

CUPCAKE is a randomized, non-comparative, multicenter, proof-of-concept phase II trial, using the Trials within Cohorts concept(1) to assess the clin...

Enrolling
Triple Negative Breast Cancer
Diagnostic Test: 68Ga-FAPI-46-PET-CT
Diagnostic Test: ctDNA monitoring
Institut Curie

Paris, France and 12 other locations

Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer (ISIdE)

ISIdE is an European, multicentric study that aims to assess the efficacy of Sacituzumab Govitecan (SG) in locally advanced or metastatic triple...

Active, not recruiting
Metastatic Breast Cancer
Triple Negative Breast Cancer
Drug: Sacituzumab govitecan

Phase 3

Unicancer
Unicancer

Villejuif, France

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer (COMPASS-TNBC)

Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer:A phase Ib/II, open-l-...

Enrolling
Breast Cancer
Drug: Durvalumab
Drug: Dato-DXd

Phase 1, Phase 2

Gustave Roussy

Villejuif, France

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) (POP-DURVA)

This study aims to evaluate the efficacy and safety of preoperative Durvalumab in patients with early small (cT1N0) triple negative ...

Active, not recruiting
Early Small (cT1N0) Triple Negative Breast Cancer
Drug: Durvalumab

Phase 2

Gustave Roussy

Villejuif, France and 2 other locations

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC (SYNERGY)

a substantial proportion of patients do not derive benefit from this approach.CD73 is an adenosine-generating enzyme overexpressed in several cancers...

Active, not recruiting
Triple Negative Breast Cancer
Drug: MEDI9447
Drug: Carboplatin

Phase 1, Phase 2

Free University of Brussels (ULB)

Paris, France and 15 other locations

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC (ETNA)

Triple-negative breast cancer (TNBC) is a group of tumors that occurs mainly in young, premenopausal women and ac ...

Enrolling
Triple-negative Breast Cancer
Drug: Pembrolizumab 25 mg/ml
Drug: Paclitaxel injection

Phase 2

Unicancer
Unicancer

Levallois-Perret, France and 43 other locations

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Placebo
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Saint-Cloud, France and 197 other locations

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen rec...

Enrolling
Breast Neoplasms
Drug: Paclitaxel
Drug: Iza-bren

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Paris, France and 294 other locations

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Villejuif, France and 372 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems